223 related articles for article (PubMed ID: 31412345)
1. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
3. Application of Bone Turnover Markers PICP and β-CTx in the Diagnosis and Treatment of Breast Cancer with Bone Metastases.
Song B; Li X; Zhou Q; Yang X; Jiang Y; Wang A
Clin Lab; 2018 Jan; 64(1):11-16. PubMed ID: 29479886
[TBL] [Abstract][Full Text] [Related]
4. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of the levels of the bone turnover markers BAP and β-CTX with bone metastasis progress in lung cancer patients].
Tang Q; Zhao H; Jia R; Liu L
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):144-7. PubMed ID: 23514943
[TBL] [Abstract][Full Text] [Related]
7. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
Bombardieri E; Martinetti A; Miceli R; Mariani L; Castellani MR; Seregni E
Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866
[TBL] [Abstract][Full Text] [Related]
8. Bone remodeling markers in the detection of bone metastases in prostate cancer.
de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
[TBL] [Abstract][Full Text] [Related]
9. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
10. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Koizumi M; Matsumoto S; Takahashi S; Yamashita T; Ogata E
Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of bone metabolism in breast cancer.
Lyubimova NV; Kozharskaya GV; Portnoi SM; Kushlinskii NE
Bull Exp Biol Med; 2014 Oct; 157(6):769-72. PubMed ID: 25342482
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the bone turnover markers in multiple myeloma.
Auzina D; Erts R; Lejniece S
Exp Oncol; 2017 Mar; 39(1):53-56. PubMed ID: 28361850
[TBL] [Abstract][Full Text] [Related]
13. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
14. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
[TBL] [Abstract][Full Text] [Related]
15. Biochemical markers for assessment of bone metastases in patients with breast cancer.
Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
[TBL] [Abstract][Full Text] [Related]
17. Markers of bone turnover in bone metastases.
Fontana A; Delmas PD
Cancer; 2000 Jun; 88(12 Suppl):2952-60. PubMed ID: 10898339
[TBL] [Abstract][Full Text] [Related]
18. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
19. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer.
Reale MG; Santini D; Marchei GG; Manna A; Del Nero A; Bianco V; Marchei P; Frati L
Int J Biol Markers; 1995; 10(1):42-6. PubMed ID: 7629426
[TBL] [Abstract][Full Text] [Related]
20. Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer.
Le Bricon T; Gay-Bellile C; Cottu P; Benlakehal M; Guillon H; Houzé P
J Clin Lab Anal; 2010; 24(1):20-4. PubMed ID: 20087950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
